Given this history, and intense lobbying from the pharmaceutical sector, the US support for the TRIPS waiver was for many a welcome surprise. Beyond patentsAs the TRIPS waiver gained public attention, many have referred to the measure as a “patent waiver”. This has obscured other intellectual property rights which are included in the original proposed TRIPS waiver: copyright, trade secrets, and designs – not just patents. The TRIPS waiver is a masthead for all of these things to happen simultaneously and urgently now. - Jocelyn Bosse, Lecturer in Intellectual Property Law, University of Reading; Hyo Yoon Kang, Reader in Intellectual Property Law, University of Kent, and Siva Thambisetty, Associate Professor of Intellectual Property Law, London School of Economics and Political ScienceThis article is republished from The Conversation under a Creative Commons license.

Source: News 24 May 10, 2021 11:48 UTC